Impact Factor
3.90
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.81
993 total citations
h5-index
39
h5 depth signal
Cited share
84.5%
180 of 213
Total citations
993
Citation footprint
Metric signal
4.65
External metric anchor
Self-citation
0.6%
6 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
417
Italy
250
United Kingdom
97
China
93
Germany
65
Citing Fields of Research
Oncology
175
Immunology
157
Hematology
89
Musculoskeletal Disorders
66
Neurodegenerative Disorders
64
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
4,721
Articles tracked across the journal lifetime
Indexed publication set
213
180 cited publications
Last 12 months
92
7.7 publications/month
Open access share
22.8%
21 OA publications in the last year
Leading citing country
United States
417 citing publications
Leading citing field
Oncology
175 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v9n1, Jan. 2000-
v9n1, Jan. 2000-
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Oncology
Hematology
Lymphomas
Diabetes
Neurodegenerative Disorders
Cardiology
Broad Categories
Drug Therapy
Hematology
Musculoskeletal Disorders
Urology
Diabetes
Allergies
Cardiology
Neurodegenerative Disorders
MeSH Descriptors
Drugs, Investigational
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/13543784.2026.2750463
Open DOI
Zovegalisib for PIK3CA -driven vascular and lymphatic malformations: a drug evaluation
1. PIK3CA encodes p110α, the catalytic subunit of phosphoinositide 3-kinase alpha (PI3Kα), a key component of the phosphoinositide 3-kinase (PI3K)–protein kinase B (AKT)–mammalian target of rapamyc...
02
DOI 10.1080/13543784.2026.2750461
Open DOI
Targeting the proteasome in Leishmania donovani : developments from preclinical to Phase I and ii trials
1. Leishmania infections display a range of clinical presentations that vary according to the species of parasite involved. Leishmaniasis in human is mainly classified into three major categories, ...
03
DOI 10.1080/13543784.2026.2748359
Open DOI
Evaluating early systemic therapies in the neoadjuvant setting for the treatment of urological cancers
04
DOI 10.1080/13543784.2026.2746598
Open DOI
Dual antigen targeting in extramedullary multiple myeloma
05
DOI 10.1080/13543784.2026.2736007
Open DOI
Safety, pharmacokinetics, pharmacodynamics and target-mediated drug disposition modeling of TST002, a sclerostin antibody, in men and postmenopausal women with low bone mineral density
1. Osteoporosis is a systemic skeletal metabolic disorder characterized by low bone mineral density (BMD) and deterioration of bone microarchitecture. With the aging of the population, its prevalen...
06
DOI 10.1080/13543784.2026.2734584
Open DOI
Emerging therapeutic strategies and clinical development of investigational agents for conventional chondrosarcoma
07
DOI 10.1080/13543784.2026.2729512
Open DOI
Innovative therapies under clinical development for ALS treatment. Part 2: biologics and natural products
The clinical trial landscape for Amyotrophic Lateral Sclerosis (ALS) is rapidly expanding despite ongoing translational challenges. Following our 2022 analysis and as a continuation of Part 1, which focused on small molecules, this revie...
08
DOI 10.1080/13543784.2026.2727499
Open DOI
Varespladib for snakebite envenoming: insights from therapeutic development and clinical trials
1. Snakebite envenoming (SBE) is a neglected tropical disease that causes significant worldwide morbidity and mortality. The World Health Organization estimates up to 138,000 deaths from snakebite ...
09
DOI 10.1080/13543784.2026.2727498
Open DOI
Up and coming early phase CAR T-cell therapy for treating relapsed or refractory large B-cell lymphoma
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape for relapsed or refractory large B-cell lymphoma (rrLBCL). Initially approved in the third-li...
10
DOI 10.1080/13543784.2026.2724869
Open DOI
HLD-0915: Could it be the breakthrough drug we need for metastatic prostate cancer?
Bibliographical & Catalog Notes
Also issued online.
Vol. 7, no. 6 (June 1998)20001117 Notice not published Printed on acid-free paper